Revance Therapeutics Inc (RVNC)
4.31
+0.07
(+1.65%)
USD |
NASDAQ |
Nov 14, 16:00
4.39
+0.08
(+1.86%)
Pre-Market: 08:48
Revance Therapeutics Free Cash Flow (Quarterly): -41.15M for Sept. 30, 2024
Free Cash Flow (Quarterly) Chart
Historical Free Cash Flow (Quarterly) Data
| Date | Value |
|---|---|
| September 30, 2024 | -41.15M |
| June 30, 2024 | -38.14M |
| March 31, 2024 | -71.11M |
| December 31, 2023 | -44.51M |
| September 30, 2023 | -55.46M |
| June 30, 2023 | -53.12M |
| March 31, 2023 | -70.37M |
| December 31, 2022 | -31.47M |
| September 30, 2022 | -58.87M |
| June 30, 2022 | -43.69M |
| March 31, 2022 | -62.73M |
| December 31, 2021 | -48.97M |
| September 30, 2021 | -50.67M |
| June 30, 2021 | -53.48M |
| March 31, 2021 | -78.79M |
| December 31, 2020 | -64.52M |
| September 30, 2020 | -56.46M |
| June 30, 2020 | -17.79M |
| March 31, 2020 | -43.95M |
| December 31, 2019 | -33.80M |
| September 30, 2019 | -33.43M |
| June 30, 2019 | -29.66M |
| March 31, 2019 | -12.50M |
| December 31, 2018 | -340.68M |
| Date | Value |
|---|---|
| September 30, 2018 | -28.44M |
| June 30, 2018 | -37.92M |
| March 31, 2018 | -12.21M |
| December 31, 2017 | -28.88M |
| September 30, 2017 | -21.99M |
| June 30, 2017 | -25.60M |
| March 31, 2017 | -21.49M |
| December 31, 2016 | -13.99M |
| September 30, 2016 | -14.51M |
| June 30, 2016 | -18.43M |
| March 31, 2016 | -16.37M |
| December 31, 2015 | -16.93M |
| September 30, 2015 | -14.26M |
| June 30, 2015 | -12.98M |
| March 31, 2015 | -14.83M |
| December 31, 2014 | -10.65M |
| September 30, 2014 | -14.72M |
| June 30, 2014 | -14.59M |
| March 31, 2014 | -22.09M |
| December 31, 2013 | -17.78M |
| September 30, 2013 | -6.827M |
| June 30, 2013 | -22.72M |
| March 31, 2013 | -6.908M |
Free Cash Flow Definition
Free cash flow measures the amount of cash left over from a time period after all operational and working capital payments are made. Free cash flow is an important metric because it allows you to view the amount actual cash is available to the company. Free cash flow is also commonly used in valuation calculations like the discounted cash flow valuation model.
Free Cash Flow (Quarterly) Range, Past 5 Years
-78.79M
Minimum
Mar 2021
-17.79M
Maximum
Jun 2020
-50.95M
Average
-51.89M
Median
Free Cash Flow (Quarterly) Benchmarks
| Recursion Pharmaceuticals Inc | -63.79M |
| Moderna Inc | -1.717B |
| Regeneron Pharmaceuticals Inc | 1.049B |
| MEI Pharma Inc | -18.00M |
| GlycoMimetics Inc | -8.896M |